RadioGenix™ System now FDA approved!

We are an emerging leader with new solutions in the field of nuclear medicine technology

Explore Our Company

Products

Products

Our innovative products and technologies are designed to meet current and future demands for medical radioisotopes. They mark a new era for nuclear medicine technology.

Supply

Supply

Medical radioisotopes are critical to meet patient healthcare needs and advance clinical research. We’ve charted the course for producing a stable, reliable and domestically sourced isotope supply.

Commitment

Commitment

Our people drive our solutions. From providing domestic supply of isotopes for patients to national security and environmental sustainability, we are committed to advancing radioisotope technology to shape a better world.

About NorthStar

We are a nuclear medicine technology company committed to providing the United States with stable, domestic and environmentally friendly radioisotope supply solutions to meet the needs of patients and advance clinical research.  Our innovative technologies have the ability to fundamentally transform the ways that medical radioisotopes are produced and distributed around the world.

Learn More About NorthStar

Press Releases
April 30, 2018
Representatives from the U.S. Department of Energy’s National Nuclear Security Administration and State of Wisconsin Join NorthStar Medical Radioisotopes’ Groundbreaking and Speaker Event

  – Event recognizes recent U.S. Food and Drug approval of NorthStar’s RadioGenix™ System for use in producing the widely used medical isotope technetium-99m (Tc-99m) from non-uranium produced molybdenum-99 (Mo-99), the first domestic production in more than 25 years – BELOIT, Wis.

Read More
In the News
February 8, 2018
FDA and NRC pave way for the first domestic supply of the most commonly used medical isotope in diagnostic imaging

FDA and NRC pave way for the first domestic supply of the most commonly used medical isotope in diagnostic imaging.  

Read More
In the News
February 8, 2018
DOE/NNSA partnership with U.S. healthcare industry results in FDA approval of domestically-produced, non-uranium based Molybdenum-99

WASHINGTON – Efforts by the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) to ensure a reliable supply of a vital medical isotope have paved the way for today’s announcement by the U.S.

Read More

How Can We Help?

Questions about company, products, supply solutions, careers or anything else?

Contact Us Today